Predigen Inc Information

A spin-out from Duke University, predigen is a global leader in the development of host gene expression signatures for use as prognostic, diagnostic, and therapeutic monitoring tools. At predigen, we’ve spent well over a decade developing the art and science of host response diagnostics. Every infection, illness, or disease is an "insult" to human health and induces a natural response directly from our genes as the body tries to counter the insult and restore health. We call this reaction the “host response”. Immediately following exposure to an insult, the host response includes changes in gene expression, where specific genes are turned on or off and drive the overall response to address the insult. This gene expression produces messenger RNA (mRNA), which in turn are the building blocks for proteins that are sent to directly counteract the insult as the body attempts to restore health. Our science is built on many years of experience, tens of thousands of patients enrolled globally, hundreds of thousands of biospecimens, and advanced machine learning. Over the past decade we have pioneered the use of host response as a means to diagnose and manage disease, and as a result we have developed robust host gene expression signatures that address unmet needs in medicine. Our portfolio includes signatures for viral, bacterial and fungal infections, sepsis, cardiovascular disease, and radiation exposure with planned work in autoimmune/inflammatory disease and cancer. Our most advanced signatures are for infectious disease, specifically the pre-symptomatic detection of viral and bacterial infections, and the ability to accurately discriminate viral from bacterial infections to enable appropriate prescription of antiviral an antibiotic medications.